Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 3
1966 1
1967 6
1968 3
1969 3
1970 1
1971 4
1972 3
1973 3
1974 3
1975 4
1976 2
1977 1
1978 6
1979 4
1980 5
1981 2
1983 2
1984 1
1985 2
1986 3
1987 8
1988 3
1989 2
1990 5
1991 7
1992 5
1993 3
1994 5
1995 6
1996 5
1997 2
2000 1
2001 3
2002 1
2003 2
2004 7
2005 10
2006 7
2007 10
2008 12
2009 9
2010 11
2011 21
2012 21
2013 19
2014 19
2015 15
2016 9
2017 13
2018 14
2019 28
2020 14
2021 25
2022 24
2023 25
2024 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

405 results

Results by year

Filters applied: . Clear all
Page 1
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Omata M, et al. Among authors: tateishi r. Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15. Hepatol Int. 2017. PMID: 28620797 Free PMC article. Review.
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Kudo M, et al. Among authors: tateishi r. Liver Cancer. 2021 Jun;10(3):181-223. doi: 10.1159/000514174. Epub 2021 May 19. Liver Cancer. 2021. PMID: 34239808 Free PMC article. Review.
Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis.
Kawamura S, Matsushita Y, Kurosaki S, Tange M, Fujiwara N, Hayata Y, Hayakawa Y, Suzuki N, Hata M, Tsuboi M, Kishikawa T, Kinoshita H, Nakatsuka T, Sato M, Kudo Y, Hoshida Y, Umemura A, Eguchi A, Ikenoue T, Hirata Y, Uesugi M, Tateishi R, Tateishi K, Fujishiro M, Koike K, Nakagawa H. Kawamura S, et al. Among authors: tateishi r. J Clin Invest. 2022 Jun 1;132(11):e151895. doi: 10.1172/JCI151895. J Clin Invest. 2022. PMID: 35380992 Free PMC article.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.
Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Fujiwara N, et al. Among authors: tateishi r. Sci Transl Med. 2022 Jun 22;14(650):eabo4474. doi: 10.1126/scitranslmed.abo4474. Epub 2022 Jun 22. Sci Transl Med. 2022. PMID: 35731891 Free PMC article.
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).
Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, Kudo M, Tateishi R; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Hasegawa K, et al. Among authors: tateishi r. Hepatol Res. 2023 May;53(5):383-390. doi: 10.1111/hepr.13892. Epub 2023 Mar 10. Hepatol Res. 2023. PMID: 36826411
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. Yamashita T, et al. Among authors: tateishi r. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12. J Gastroenterol. 2020. PMID: 31720835 Free PMC article. Clinical Trial.
Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis.
Soeda K, Sasako T, Enooku K, Kubota N, Kobayashi N, Ikushima YM, Awazawa M, Bouchi R, Toda G, Yamada T, Nakatsuka T, Tateishi R, Kakiuchi M, Yamamoto S, Tatsuno K, Atarashi K, Suda W, Honda K, Aburatani H, Yamauchi T, Fujishiro M, Noda T, Koike K, Kadowaki T, Ueki K. Soeda K, et al. Among authors: tateishi r. Nat Commun. 2023 Oct 18;14(1):6584. doi: 10.1038/s41467-023-42334-y. Nat Commun. 2023. PMID: 37852976 Free PMC article.
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial).
Takayama T, Hasegawa K, Izumi N, Kudo M, Shimada M, Yamanaka N, Inomata M, Kaneko S, Nakayama H, Kawaguchi Y, Kashiwabara K, Tateishi R, Shiina S, Koike K, Matsuyama Y, Omata M, Makuuchi M, Kokudo N. Takayama T, et al. Among authors: tateishi r. Liver Cancer. 2021 Dec 29;11(3):209-218. doi: 10.1159/000521665. eCollection 2022 Jun. Liver Cancer. 2021. PMID: 35949295 Free PMC article.
405 results